Intest Res.  2016 Apr;14(2):152-163. 10.5217/ir.2016.14.2.152.

Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease

• Wu KC
• Ran ZH
• Gao X
• Chen M
• Zhong J
• Sheng JQ
• Kamm MA
• Travis S
• Wallace K
• Mostafa NM
• Shapiro M
• Li Y
• Thakkar RB
• Robinson A

• KMID: 2425288
• DOI: http://doi.org/10.5217/ir.2016.14.2.152

Abstract

BACKGROUND/AIMS
This was a Phase 2 study (NCT02015793) to evaluate the pharmacokinetics, safety, and efficacy of adalimumab in Chinese patients with Crohn's disease (CD).
METHODS
Thirty, adult Chinese patients with CD (CD Activity Index [CDAI] 220-450; high-sensitivity [hs]-C-reactive protein [CRP] ≥3 mg/L) received double-blind adalimumab 160/80 mg or 80/40 mg at weeks 0/2, followed by 40 mg at weeks 4 and 6. An open-label extension period occurred from weeks 8-26; patients received 40 mg adalimumab every other week. Serum adalimumab concentration and change from baseline in fecal calprotectin (FC) were measured during the double-blind period. Clinical remission (CDAI <150), response (decrease in CDAI ≥70 points from baseline), and change from baseline in hs-CRP were assessed through week 26. Nonresponder imputation was used for missing categorical data and last observation carried forward for missing hs-CRP/FC values. No formal hypothesis was tested. Adverse events were monitored.
RESULTS
Mean adalimumab serum concentrations during the induction phase were 13.9-18.1 µg/mL (160/80 mg group) and 7.5-9.5 µg/mL (80/40 mg group). During the double-blind period, higher remission/response rates and greater reductions from baseline in hs-CRP and FC were observed with adalimumab 160/80 mg compared to that with 80/40 mg. Adverse event rates were similar among all treatment groups.
CONCLUSIONS
Adalimumab serum concentrations in Chinese patients with CD were comparable to those observed previously in Western and Japanese patients. Clinically meaningful remission rates and improvement in inflammatory markers were achieved with both dosing regimens; changes occurred rapidly with adalimumab 160/80 mg induction therapy. No new safety signals were reported.

Keyword

Crohn disease; Anti-tumor necrosis factor; Adalimumab

MeSH Terms

Adult
Asian Continental Ancestry Group*
Crohn Disease*
Humans
Leukocyte L1 Antigen Complex
Pharmacokinetics
Leukocyte L1 Antigen Complex

Figure

• 

  Fig. 1 Study design. a, Dose escalation to 80 mg adalimumab (ADA) every other week (EOW) at/after week 12 for disease flares/non-response. OL, Open-label.

• 

  Fig. 2 Flow diagram of patient disposition. ADA, Adalimumab. Patient disposition: number of patients enrolled, randomized, and completed the study.

• 

  Fig. 3 Mean adalimumab serum concentrations over time. Mean adalimumab concentrations during the double-blind period in adalimumab-treated Chinese patients with CD. Error bars represent SD.

• 

  Fig. 4 Clinical remission, clinical response, and CDAI over time. Percentages of patients in remission (CDAI <150) over time (A). Percentages of patients achieving CR-70 (decrease from baseline CDAI of ≥70 points) over time (B). Percentages of patients achieving CR-100 (decrease from baseline CDAI of ≥100 points) over time (C). Error bars represent 95% CI. Non-responder imputation was used for data analysis.

• 

  Fig. 5 Changes in laboratory parameters over time. Median changes from baseline in high-sensitivity-CRP protein (hs-CRP) (A), fecal calprotectin (FC) (B), and mean changes from baseline in albumin (C) concentrations over time. Error bars represent SD. Data were analyzed using last observation carried forward.

Reference

1. Hanauer SB, Sandborn W. Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol. 2001; 96:635–643. PMID: 11280528.

2. Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study. Gastroenterology. 2013; 145:158–165. PMID: 23583432.

3. Zeng Z, Zhu Z, Yang Y, et al. Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: a prospective population-based study. J Gastroenterol Hepatol. 2013; 28:1148–1153. PMID: 23432198.

4. Zhao J, Ng SC, Lei Y, et al. First prospective, population-based inflammatory bowel disease incidence study in mainland of China: the emergence of "western" disease. Inflamm Bowel Dis. 2013; 19:1839–1845. PMID: 23669403.

5. Prideaux L, Kamm MA, De Cruz PP, Chan FK, Ng SC. Inflammatory bowel disease in Asia: a systematic review. J Gastroenterol Hepatol. 2012; 27:1266–1280. PMID: 22497584.

6. Ooi CJ, Makharia GK, Hilmi I, et al. Asia Pacific Consensus Statements on Crohns disease. Part 1: Definition, diagnosis, and epidemiology: (Asia Pacific Crohn's Disease Consensus-Part 1). J Gastroenterol Hepatol. 2016; 31:45–55. PMID: 25819140.

7. Ng SC, Zeng Z, Niewiadomski O, et al. Early course of inflammatory bowel disease in a population-based inception Cohort study from 8 countries in Asia and Australia. Gastroenterology. 2016; 150:86–95. PMID: 26385074.

8. Ooi CJ, Makharia GK, Hilmi I, et al. Asia-Pacific consensus statements on Crohn's disease. Part 2: Management. J Gastroenterol Hepatol. 2016; 31:56–68. PMID: 25819311.

9. Zheng JJ, Zhi P, Wang YM, et al. Short-term study of infliximab treatment for Crohn's disease in China. J Dig Dis. 2011; 12:105–109. PMID: 21401895.

10. Xiao YL, Chen BL, He Y, et al. The clinical and endoscopic efficacy of step-up and top-down infliximab therapy in Crohn's disease. Zhonghua Nei Ke Za Zhi. 2012; 51:100–103. PMID: 22490808.

11. Zhou Y, He H, Wang P, et al. Infliximab for the treatment of Crohn's disease: efficacy and safety in a Chinese single-center retrospective study. Eur J Gastroenterol Hepatol. 2015; 27:1270–1275. PMID: 26275085.

12. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132:52–65. PMID: 17241859.

13. Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology. 2012; 142:1102–1111. PMID: 22326435.

14. Watanabe M, Hibi T, Lomax KG, et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. J Crohns Colitis. 2012; 6:160–173. PMID: 22325170.

15. Chiu YL, Rubin DT, Vermeire S, et al. Serum adalimumab concentration and clinical remission in patients with Crohn's disease. Inflamm Bowel Dis. 2013; 19:1112–1122. PMID: 23584130.

16. Watanabe M, Hibi T, Mostafa NM, et al. Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease. J Crohns Colitis. 2014; 8:1407–1416. PMID: 24874893.

17. Huang F, Zhang FC, Bao CD, et al. Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study. Zhonghua Nei Ke Za Zhi. 2009; 48:916–921. PMID: 20079321.

18. Huang F, Gu J, Zhu P, et al. Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial. Ann Rheum Dis. 2014; 73:587–594. PMID: 23475983.

19. Huang F, Zhang J, Zheng Y, et al. A multicenter, double-blind, randomized, placebo-controlled clinical trial of etanercept treatment of Chinese patients with active ankylosing spondylitis. Zhonghua Nei Ke Za Zhi. 2011; 50:1043–1047. PMID: 22333175.

20. Huang F, Zhang J, Huang JL, et al. A multicenter, double-blind, placebo-controlled, randomized, phase III clinical study of etanercept in treatment of ankylosing spondylitis. Zhonghua Nei Ke Za Zhi. 2010; 49:741–745. PMID: 21092442.

21. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis. 2004; 10:661–665. PMID: 15472532.

22. Zilberman L, Maharshak N, Arbel Y, et al. Correlated expression of high-sensitivity C-reactive protein in relation to disease activity in inflammatory bowel disease: lack of differences between Crohn's disease and ulcerative colitis. Digestion. 2006; 73:205–209. PMID: 16837810.

23. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006; 130:323–333. PMID: 16472588.

24. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007; 56:1232–1239. PMID: 17299059.

25. Schreiber S, Reinisch W, Colombel JF, et al. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. J Crohns Colitis. 2013; 7:213–221. PMID: 22704916.

26. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006; 55:426–431. PMID: 16474109.

27. Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut. 2008; 57:1518–1523. PMID: 18566104.

28. Mosli MH, Zou G, Garg SK, et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am J Gastroenterol. 2015; 110:802–819. PMID: 25964225.

29. Colombel JF, Sandborn WJ, Panaccione R, et al. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm Bowel Dis. 2009; 15:1308–1319. PMID: 19434735.

30. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis. 2013; 72:517–524. PMID: 22562972.

31. Wang L, Zhang H, Ruan Y, et al. Tuberculosis prevalence in China, 1990-2010; a longitudinal analysis of national survey data. Lancet. 2014; 383:2057–2064. PMID: 24650955.

32. HUMIRA [package insert]. North Chicago, IL: AbbVie Inc.;2015.